文献速递免疫规划职业卫生

西班牙国家卫生系统工勤人员对常规乙肝疫苗无应答者接种佐剂疫苗的研究

Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines.
PubMed 文献 · Vaccine · 2020-12-15

该研究为4期开放标签单组预防性临床试验,纳入67名对常规乙肝疫苗无应答的西班牙国家卫生系统工勤人员,评估Fendrix®佐剂疫苗的疗效。结果显示,首剂后68.66%产生阳性应答,全程总阳性应答率达94.02%,未发生严重不良事件。

要点

  • 对常规乙肝疫苗无应答的工勤人员,Fendrix®佐剂疫苗总阳性应答率达94.02%。
  • 首剂Fendrix®后68.66%即产生阳性应答,后续剂量可进一步提高应答率。
  • 研究中未发生严重不良事件,提示该疫苗用于健康无应答者安全性良好。

核心结论

  • Fendrix®佐剂疫苗是西班牙国家卫生系统工勤人员中对常规乙肝疫苗无应答者的可行替代疫苗。
  • 健康无应答者接种Fendrix®后应答比例很高,且未发生不良事件。

研究设计与样本

  • 干预性4期单组开放标签预防性临床试验,无随机化和盲法。
  • 纳入67名18至64岁、有生物风险的西班牙国家卫生系统工勤人员(含在卫生中心实习的大学生),均被归类为对常规乙肝疫苗无应答。
  • 无应答定义为接种6剂20 μg常规疫苗(两个完整疗程)后抗HBsAb滴度<10 mUI/ml。

主要发现

  • 首剂Fendrix®后68.66%(46/67)产生阳性应答。
  • 第二剂后57.14%(12/21)产生阳性应答;第三剂后22.22%(2/9)产生阳性应答;末剂后42.96%(3/7)产生阳性应答。
  • 总体94.02%(64/67)的参与者对Fendrix®产生阳性应答。
  • 未发生严重不良事件。

关键数值与推荐

  • Fendrix®基础免疫为4剂,每剂0.5 ml,于首剂后1个月、2个月和6个月接种。
  • 任一剂次达到阳性后即终止研究,不再接种后续剂次。
  • 主要结局为首次Fendrix®剂量前及每剂接种后1个月抗HBs抗体测定。

临床怎么用

  • 对于常规乙肝疫苗无应答的卫生工勤人员,可考虑使用Fendrix®佐剂疫苗进行再接种。
  • 接种过程中应监测抗HBs抗体应答,一旦阳性可终止后续剂次。
  • 需关注接种后30天内不良事件。

局限性

  • 单组设计,无随机化和盲法,缺乏对照组。
  • 样本量较小(67人),且仅纳入健康无应答者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TRIAL DESIGN: An interventional, phase 4, single group assignment, without masking (open label), preventive clinical trial was carried out in health workers with biological risk in their tasks, who have been filed as non-responders to conventional vaccination against Hepatitis B. METHODS: 67 health workers with biological risk in their tasks, who have been filed as non-responders to conventional vaccination against Hepatitis B, were enrolled in the Clinical Trial. All participants were from 18 years up to 64 years old. INCLUSION CRITERIA: NHS workers -including university students doing their internships in health centres dependent on the National Health System (inclusion of students is regulated and limited by specific instructions on labour prevention in each autonomous community)- classified as non-responders. The criteria defining them as non-responders to the conventional hepatitis B vaccine is anti HBsAb titers < 10 mUI/ml following the application of six doses of conventional vaccine at 20 μg doses (two complete guidelines). The objective of this study was to provide Health workers-staff with an additional protection tool against hepatitis B infection, and to evaluate the efficacy of the adjuvanted vaccine in healthy non-responders to conventional hepatitis B vaccine. The primary outcome was the measurement of antibody antiHBs before the first Fendrix® dose and a month after the administration of each dose. Other outcome was collection of adverse effects during administration and all those that could be related to the vaccine and that occur within 30 days after each dose. In this study, only one group was assigned. There was no randomization or masking. RESULTS: The participants were recruited between April 13, 2018 and October 31, 2019. 67 participants were enrolled in the Clinical Trial and included the analyses. The primary immunisation consists of 4 separate 0.5 ml doses of Fendrix®, administered at the following schedule: 1 month, 2 months and 6 months from the date of the first dose. Once the positivity was reached in any of the doses, the participant finished the study and was not given the following doses. 68.66% (46 out 67) had a positive response to first dose of Fendrix®. 57.14% (12 out 21) had a positive response to second dose of Fendrix®. 22.22% (2 out 9) had a positive response to third dose of Fendrix and 42.96% (3 out 7) had a positive response to last dose of Fendrix®. Overall, 94.02% (64 out 67) of participants had a positive response to Fendrix®. No serious adverse event occurred. CONCLUSIONS: The use of Fendrix®, is a viable vaccine alternative for NHS workers classified as "non-responders". Revaccination of healthy non-responders with Fendrix®, resulted in very high proportions of responders without adverse events. TRIAL REGISTRATION: The trial was registered in the Spanish National Trial Register (REEC), ClinicalTrials.gov and inclusion has been stopped (identifier NCT03410953; EudraCT-number 2016-004991-23). FUNDING: GRS 1360/A/16: Call for aid for the financing of research projects in biomedicine, health management and socio-health care to be developed in the centres of the Regional Health Management of Autonomous Community of Castile-Leon. In addition, this work has been supported by the Spanish Platform for Clinical Research and Clinical Trials, SCReN (Spanish Clinical Research Network), funded by the Subdirectorate General for Research Evaluation and Promotion of the Carlos III Health Institute (ISCIII), through the project PT13/0002/0039 and project PT17/0017/0023 integrated in the State Plan for R&D&I 2013-2016 and co-financed by and the European Regional Development Fund (ERDF).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Bravo-Grande JL, Asunción Blanco-González M, de la Torre-Robles JM, et al. Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines. Vaccine. 2020. PMID: 33334613. doi:10.1016/j.vaccine.2020.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。